a comparison of egfr mutation testing methods in lung carcinoma direct sequencing, real-time pcr and immunohistochemistry表皮生长因子受体突变测试方法的比较肺癌直接测序,实时pcr和免疫组织化学.pdfVIP

A Comparison of EGFR Mutation Testing Methods in Lung Carcinoma: Direct Sequencing, Real-time PCR and Immunohistochemistry ´ 1 1 ´ 1 1 ´ 1 1 Barbara Angulo , Esther Conde , Ana Suarez-Gauthier , Carlos Plaza , Rebeca Martınez , Pilar Redondo , 1 ´ 1,2 3 1,2 ´ ´ 1 Elisa Izquierdo , Belen Rubio-Viqueira , Luis Paz-Ares , Manuel Hidalgo , Fernando Lopez-Rıos * ´ ´ 1 Laboratorio de Dianas Terapeuticas, Faculty of Medicine, Centro Integral Oncologico ‘‘Clara Campal’’, Hospital HM Universitario Sanchinarro, Universidad San Pablo-CEU, Madrid, Spain, 2 Gastrointestinal Cancer Clinical Research Unit, Spanish National Cancer Research Centre, Madrid, Spain, 3 Department of Oncology, Instituto de ´ Biomedicina de Sevilla (IBIS) Hospital Universitario Virgen del Rocıo, Sevilla, Spain Abstract The objective of this study is to compare two EGFR testing methodologies (a commercial real-time PCR kit and a specific EGFR mutant immunohistochemistry), with direct sequencing and to investigate the limit of detection (LOD) of both PCR- based methods. We identified EGFR mutations in 21 (16%) of the 136 tumours analyzed by direct sequencing. Interestingly, the Therascreen EGFR Mutation Test kit was able to characterize as wild-type one tumour that co